Pharmascience Canada is announced the launch of Pr pms-PALBOCICLIB. Pr pms-PALBOCICLIB (palbociclib) is a prescription treatment indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with:
An aromatase inhibitor as initial endocrine-based therapy in post-menopausal women or men;
Fulvestrant in patients with disease progression after prior endocrine therapy. Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist.
Pr pms-PALBOCICLIB is available in the following dosage forms:
- 75 mg: box containing 3 weekly blister packs, total 21 tablets
- 100 mg: box containing 3 weekly blister packs, total 21 tablets
- 125 mg: box containing 3 weekly blister packs, total 21 tablets
Pr pms-PALBOCICLIB tablets is the generic equivalent of IBRANCE®.
"We are proud to announce the launch of Pr pms-PALBOCICLIB; a product that showcases our local expertise and enhances our expanding specialty portfolio. This medication highlights Pharmascience's leadership in supporting our local industry and Canadian patients. We are excited to offer solutions to reinforce our commitment to pharmaceutical excellence and have a positive impact on patients' lives." Said Mike Dutton, Vice-President and General Manager, Pharmascience Canada. "Our team has worked tirelessly to ensure that Pr pms-PALBOCICLIB meets the quality expectations of Canadian customers and patients".
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!